Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02302521 · ClinicalTrials.gov registry record

Motion Immune Magnetic Resonance Imaging (MRI)

A clinical trial of Parkinson's Disease, sponsored by Duke University.

Completed
Registry status
16
Enrollment target
1
Study location

NCT02302521: Completed study of Parkinson's Disease, sponsored by Duke University.

NCT02302521 is a study of Parkinson's Disease that has completed, run by Duke University. The registered enrollment target is 16 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02302521, a study of Parkinson's Disease, has completed, sponsored by Duke University.

COMPLETED
Registry status
16 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate our recently developed MRI reconstruction strategy for producing artifact-free neuro and abdominal MRI data. The new reconstruction strategies, including 1) REKAM and 2) MUSE, are capable of effectively removing motion-related artifacts resulting from global and local motion during neuro and free-breathing abdominal MRI scans, without modifying the MRI pulse sequences and protocols that are currently used in clinical scans. The study team aims to recruit 60 subjects across multiple challenge patient populations: 10 healthy young adults (age 20-30) and 10 healthy older adults (aged 50-70) for abdominal MRI, as well as 20 tremor dominant PD patients and 20 children (age 4-8) for brain MRI scans. There are no known risks in taking MRIs and a unique code will be assigned to each participant to protect their PHI.

Primary Outcome

The ratings will be compared to compare the quality of images processed with MUSE versus conventional reconstruction methods

Conditions Studied

Interventions

  • DEVICE Multiplex Sensitivity Encoding (MUSE)

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2015-05-28
Est. Completion 2016-11-26
Duke University

1,725 total trials

What the finished NCT02302521 record still lists

NCT02302521 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Multiplex Sensitivity Encoding (MUSE) is the first listed.

NCT02302521 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02302521 about?

NCT02302521 is a clinical study titled "Motion Immune Magnetic Resonance Imaging (MRI)". The purpose of this study is to evaluate our recently developed MRI reconstruction strategy for producing artifact-free neuro and abdominal MRI data. The new reconstruction strategies, including 1) REKAM and 2) MUSE, are capable of effectively removing motion-related artifacts resulting from global ...

What is the current status of trial NCT02302521?

This trial is currently completed. The enrollment target is 16 participants. The study started on 2015-05-28. Estimated completion is 2016-11-26.

What conditions does trial NCT02302521 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT02302521?

The interventions under investigation include: Multiplex Sensitivity Encoding (MUSE) (DEVICE).

Who is sponsoring clinical trial NCT02302521?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02302521 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02302521's enrollment target sits among peer trials

16 137th of 158 higher than 22 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02302521, the US trial registry maintained by the National Library of Medicine. NCT02302521 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.